Zepbound demonstrated 20.9% mean body weight reduction in SURMOUNT-1 at 15mg surpassing semaglutides 15% benchmark and establishing dual GIP/GLP-1 agonism as the dominant next-generation obesity mechanism
If no medication is prescribed after evaluation, Ro says the initial payment is refunded
Other GLP1 receptor agonists, such as Trulicity (dulaglutide), Wegovy (also semaglutide but at a higher dose for weight loss), and Victoza (liraglutide), offer similar mechanisms but vary in dosing frequency, cost, and clinical indications
5, 6, 8, 13, 14 This indicates that liraglutide treatment uncouples the increase in soluble leptin receptors that normally occurs during weight loss, thereby preventing the decrease in free leptin and thus preventing the increase in food-seeking behavior during weight loss maintenance